Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aroeira vs Omeprazole in Functional Dyspepsia
NCT04069286Phase 3Not yet recruiting
- Sponsor
- Infinant Health
- Start
- Mar 2025
- Primary completion
- Jul 2026
01
Overview
Phase 3, randomised, double-blind trial in functional dyspepsia (FD) (2 arms), sponsored by Infinant Health. Primary endpoint: Complete relief of dyspepsia symptoms at 30 days. Planned start Mar 2025; status: not yet recruiting.
02
Conditions
functional dyspepsia (FD)
Beyond the preview
Go deeper on NCT04069286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04069286.